Healthcare >> Sector Roundtables >> January 26, 2004


DOUGLAS LOE is healthcare and biotechnology analyst at Dlouhy Merchant Group. Dr. Loe has covered the Canadian biotechnology sector since 2000 and joined the Dlouhy team in August 2002. He holds a MBA from Queen's University and a PhD in biochemistry from the University of Guelph, working in the area of cancer chemotherapy and multidrug resistance, followed by post-doctoral training at the Queen's University Cancer Research Laboratories. Prior to commencing his career in financial analysis, Dr. Loe worked as a consultant to Molecular Mining Corporation and MDS Inc. To date, Dr. Loe has published 24 abstracts and 17 peer- reviewed manuscripts and review articles related to P-glycoprotein and MRP-mediated multidrug resistance. Profile
BARBARA A. JOHNSTON has been a Life Sciences Analyst with Haywood Securities Inc. in Vancouver, British Columbia, since 2000. In this position, Dr. Johnston assesses both private and public biotechnology and healthcare companies for investment opportunities. She also researches and evaluates value and growth prospects for private biotech and medical device companies. Prior to joining Haywood Securities, Dr. Johnston served for a year as the Associate Director of Professional Services at Charles River Laboratories in Wilmington, Massachusetts. In this role, she professionally oversaw the world's largest research animal diagnostic laboratory. Before that, Dr. Johnston spent 12 years as the Vavarium Director of Animal Health Resources at the Fred Hutchinson Cancer Research Center in Seattle. Dr. Johnston received her board certification from the American College of Laboratory Animal Science in 1994 after performing her residency in Laboratory Animal Medicine at the University of Washington. She received her Doctorate in Veterinary Medicine from Washington State University in 1985, after completing her bachelor's degree in Biology and Fisheries from the University of Washington in 1981. Profile
TWST: Barbara, how did the Canadian biotech stocks do in 2003 from a

market perspective?

Dr. Johnston: The sector as a whole did well in North America, and I

think that Canadian biotech has